NCT04676516View on ClinicalTrials.gov

A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Breast Cancer
Interventions
DRUG

GSK3326595

GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.

Trial Locations (1)

N6A 4V2

St. Joseph's Health Care London, London

Sponsors
All Listed Sponsors
collaborator

Ontario Institute for Cancer Research

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

London Regional Cancer Program, Canada

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

Ottawa Hospital Research Institute

OTHER